Scarica l'app Stockscreener
44.99
1.08%
0.48
Dopo l'orario di chiusura:
44.91
-0.08
-0.18%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALKS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$44.51
Aprire:
$45.25
Volume 24 ore:
7.73M
Relative Volume:
3.28
Capitalizzazione di mercato:
$7.50B
Reddito:
$1.56B
Utile/perdita netta:
$152.72M
Rapporto P/E:
50.02
EPS:
0.8994
Flusso di cassa netto:
$221.80M
1 W Prestazione:
+0.16%
1M Prestazione:
+20.97%
6M Prestazione:
+61.78%
1 anno Prestazione:
+53.39%
Intervallo 1D:
$43.98
$45.76
Intervallo di 1 settimana:
$43.34
$45.76
Portata 52W:
$25.16
$45.76
Alkermes Plc Stock (ALKS) Company Profile
Nome
Alkermes Plc
Settore
Telefono
00-353-1-772-8000
Indirizzo
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
44.99 | 7.50B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
15.63 | 49.39B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
8.96 | 39.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.48 | 36.66B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
78.71 | 33.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
536.59 | 22.78B | 3.17B | 1.29B | 1.01B | 27.09 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2025-11-11 | Iniziato | Truist | Buy |
| 2025-09-26 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Iniziato | Wells Fargo | Overweight |
| 2025-07-15 | Iniziato | Goldman | Buy |
| 2025-06-17 | Aggiornamento | UBS | Neutral → Buy |
| 2025-05-28 | Iniziato | Needham | Buy |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Aggiornamento | UBS | Sell → Neutral |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-11-05 | Aggiornamento | Stifel | Hold → Buy |
| 2024-06-17 | Iniziato | TD Cowen | Buy |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-20 | Downgrade | UBS | Neutral → Sell |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Iniziato | UBS | Neutral |
| 2022-11-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Iniziato | Piper Sandler | Neutral |
| 2022-04-22 | Ripresa | Goldman | Buy |
| 2022-04-20 | Iniziato | Goldman | Buy |
| 2022-01-27 | Aggiornamento | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Iniziato | Citigroup | Neutral |
| 2021-10-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-09-02 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2020-02-14 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Reiterato | H.C. Wainwright | Neutral |
| 2020-02-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-01-31 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-31 | Iniziato | H.C. Wainwright | Neutral |
| 2019-05-01 | Downgrade | Citigroup | Buy → Neutral |
| 2018-12-19 | Downgrade | Goldman | Neutral → Sell |
| 2018-12-14 | Iniziato | Wolfe Research | Underperform |
| 2018-12-13 | Downgrade | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Iniziato | Piper Jaffray | Neutral |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-06-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
Mostra tutto
Alkermes Plc Borsa (ALKS) Ultime notizie
Alkermes: "Buy" On Avadel Acquisition And Positive NT2 Data With Alixorexton (NASDAQ:ALKS) - Seeking Alpha
Did Positive Vibrance-2 Data for Alixorexton Just Shift Alkermes' (ALKS) Investment Narrative? - simplywall.st
Alkermes stock hits 52-week high at 45.76 USD By Investing.com - Investing.com India
Alkermes presents detailed positive results from Vibrance-2 phase 2 study of Alixorexton in adults with narcolepsy type 2 at SLEEP 2026 - MSN
Alkermes stock hits 52-week high at 45.76 USD - Investing.com
Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday - Benzinga
Alkermes (ALKS) Study Results Highlight Potential Benefits for N - GuruFocus
Needham raises Alkermes stock price target on narcolepsy drug data By Investing.com - Investing.com Nigeria
Needham raises Alkermes stock price target on narcolepsy drug data - Investing.com
H.C. Wainwright reiterates Alkermes stock rating on trial data By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Alkermes stock rating on trial data - Investing.com
ALKS Maintains Buy Rating by Needham -- Price Target Raised to $54.00 - GuruFocus
Alkermes Plc (ALKS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alkermes Plc (ALKS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Alkermes Plc (ALKS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alkermes Plc (ALKS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alkermes Plc (ALKS) Institutional Confidence - TradingKey
Alkermes Plc (ALKS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
What Does the Recent Insider Sale by Alkermes' VP of Finance Signify - Kavout
Alkermes (ALKS) Shares Fall 31% Despite Positive Phase 2 Trial R - GuruFocus
Alkermes (ALKS) Advances Narcolepsy Treatment with Positive Phas - GuruFocus
Alkermes reports positive phase 2 results for narcolepsy drug By Investing.com - Investing.com India
Alkermes plummets on mid-stage Alixorexton data for narcolepsy - MSN
Alkermes Plc (ALKS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Alkermes Plc (ALKS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alkermes reports positive phase 2 results for narcolepsy drug - Investing.com
Alkermes Plc (ALKS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Alkermes stock jumps as narcolepsy drug hits trial goals - Investing.com
Alkermes stock jumps as narcolepsy drug hits trial goals By Investing.com - Investing.com UK
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026 - The Daily Tribune News
REGBlackRock GroupSAR 6- ALKERMES PLC - TradingView
Alkermes Granted Orphan Drug Designations for Alixorexton in US, Europe - Sleep Review
Alkermes plc Stock (IE00B56GVS15): Orphan-Drug Boost For Sleep Disorder Candidate Alixorexton - AD HOC NEWS
Alkermes receives transatlantic orphan drug designations for alixorexton - grafa.com
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe - BioSpace
Alkermes’ alixorexton receives orphan drug designations in US, EU By Investing.com - Investing.com Australia
Alkermes’ alixorexton receives orphan drug designations in US, EU - Investing.com
Alkermes (ALKS) wins orphan drug designations in U.S. and Europe for alixorexton - Stock Titan
New narcolepsy drug wins rare-disease backing in U.S., Europe - Stock Titan
Alkermes Plc (ALKS) Stock Analysis: Growth Potential With A 28.20% Revenue Surge - DirectorsTalk Interviews
Why (ALKS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Insider Sell: Christopher Wright Sells 2,000 Shares of Alkermes PLC (ALKS) - GuruFocus
Alkermes (ALKS) director sells 2,000 shares under Rule 10b5-1 plan - Stock Titan
Alkermes plc (ALKS) Rule 144 notice: 2,000 vested RSU shares listed - Stock Titan
Alkermes' alixorexton gains FDA orphan drug status for idiopathic hypersomnia - MSN
Alkermes (ALKS) Receives FDA Orphan Designation for Alixorexton - GuruFocus
Alkermes (ALKS) Receives Orphan Drug Designation for Alixorexton - GuruFocus
Alkermes touts orexin ambitions as Alixorexton enters phase 3 and CEO transition nears - MSN
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears - Yahoo Finance
ALKS: Orexin agonist program advances with strong clinical data, strategic acquisition, and leadership transition - TradingView
ALKS: Orexin agonist advances, Avadel integration, and pipeline expansion drive strategic momentum - TradingView
Alkermes Plc Azioni (ALKS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
11.23%
0.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):